All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Psychiatry and Neuroscience

Sign up for email alert when new content gets added: Sign up

Soraya L Valles
University of Valencia, Spain, Email: [email protected]

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]

Summary: Dementia Care 2020 welcomes attendees,presenters, and exhibitors from all over the world to Paris, France. We are delighted to invite you all to attend and register for the “11th International Conference on Dementia and Dementia Care”, which is going to be held during February 19-20, 2020 at Paris, France. The Scientific committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We are very glad to invite you to join us at Dementia Care 2020, where you will be sure to have a meaningful experience with scholars from around the world. We all look forward to meeting you at Paris, France.

Scope and Importance:

The conference will be organized around the theme “Dementia Care 2020: Improvement of the situation of people living with dementia and their carers” to bring together the Scientists, Professors, Health Organizations, Social Workers, Persons living with Dementia, all those providing care and treatment to patients with Dementia. Conference theme focuses on discussing the leading advancements in the field of Dementia Research and in Dementia Care. Also, this conference will provide scope for all the proficient people in the field of Neuroscience and Psychiatry to accomplish their research relationships with each other and to discover global associates for future collaboration. The number of people with dementia in France in 2017 as being 1,272,317. This represents 2.09% of the total population of 60,964,145. The number of people with dementia as a percentage of the population is somewhat higher than the EU average of 1.55%.

The following table shows the estimated number of people with dementia between 30 and 59 and for every 5-year age group thereafter for people living with dementia.


Why Paris?

Paris, France’s capital is a city of love, city of lights and an International Melting Pot. It is the most visited tourist destination in the world, with over 45 million visitors annually, it is very easy to arrive in Paris with huge expectations: of grand vistas and of budding writers in every café. On all levels – historical, architectural, and cultural – there is something all about Paris that will fascinate you.

In France, more than 1,175,000 people are living with Alzheimer’s disease, and more than 200,000 people are diagnosed with Alzheimer’s or another dementia each year. Worldwide, at least 44 million people are living with dementia, making the disease and condition a global health crisis that must be addressed.

Both the Government and the Charities help the universities and the Collaborative Research centres to carry out Dementia research in developing novel medicines for dementia. The list of Governmental funding agents, Non-Governmental Organizations and Companies providing funds for Dementia Research in Europe includes the following,

• Alzheimer’s Europe

• Medical Research Council (MRC)

• The Dementia Discovery Fund

• Alzheimer’s Society

• UK Department of Health

• Biogen


• Johnson and Johnson

• Lilly

• Pfizer

• Takeda

Drugs that are available in the market for the treatment of dementia includes Memantine, Donepezil, Rivastigmine, Galantamine. Among these drugs Donepezil is considered as the most effective one, since it has cured dementia in about 59,931 people. It is also reported that about 30,000 people are treated with Rivastigmine. The Memantine ranks third in treating about 14,640 patients, the Galantamine drug cures Dementia in about 10,000 patients.


+44 1467840001

Recommended Conferences

3rd Annual Congress on Psychiatry

London, United Kingdom